Impact of a Gluten-free Diet on Quality of Life in Patients With Axial Spondyloarthritis. (GlutenSPA)

Impact of a Gluten-free Diet on Quality of Life in Patients With Axial Spondyloarthritis: Study Protocol of a Randomized Double-blind Placebo-controlled Trial

Subclinical intestinal inflammation and gut dysbiosis have been reported in patients with spondyloarthritis (SpA). In common practice, rheumatologists are increasingly confronted with patients with inflammatory rheumatism who are on gluten-free diets (GFDs), despite the lack of reliable data from controlled studies. This study aims to determine the impact of a GFD on the quality of life of patients with axial SpA.

Study Overview

• Status: Recruiting
• Conditions: Ankylosing Spondyloarthritis
• Intervention / Treatment: Dietary supplement: Gluten-Free Diet; Dietary supplement: Gluten Diet

Detailed Description

The GlutenSpA study is a 24-week, randomized, double-blinded, placebo-controlled, multicenter trial. Patients with axial SpA (n=200) will follow a 16-week GFD and be randomly assigned (1:1) to an experimental or control arm. In the experimental arm with receive at least 6 gluten-free breads per day + 200 g of gluten-free penne pasta per week + 6 rice flavor capsules per day. The control arm will receive at least 6 gluten-containing breads per day + 200 g of gluten-containing penne pasta per week + 6 vital gluten-containing capsules per day.

At baseline, the dietician will explain to the patients how to properly follow a GFD during a face-to-face interview. The patient's compliance to the GFD will be evaluated by the dietician at S2, S16, an S24 using an online 3-day alimentary questionnaire.

The bread and penne pasta were chosen for their visual resemblance and similar taste to maximize the blindness of the study. In order to reach the daily amount of gluten in a standard diet (estimated in France between 10 and 15 g/d) in the control arm, each day patients will have to ingest six capsules of vital gluten wheat made for the study. Vital gluten flour is an over-the-counter food supplement used to enrich a protein diet or as a base for making products, such as seitan. Capsules will be made using commercially available vital gluten and contain 0.35 g of gluten per capsule. The total amount of gluten in the control arm will be approximately 10.5 g/day.

After the 16-week GFD, patients will be offered to follow or not follow the GFD according to their own decision for an 8-week open-labelled follow-up period. The study duration for each patient is 24 weeks. The patient recruitment is expected to last 2 years

• Study Type: Interventional
• Enrollment (Estimated): 200
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Lise Laclautre, Pharm D; Phone Number: 334.73.754.963; Email: promo_interne_drci@chu-clermontferrand.fr

Study Locations

• France
  • Bordeaux, France, 33000
    • Not yet recruiting
    • CHU de Bordeaux
    • Principal Investigator: Thierry SHAEVERBEKE, MD, PhD
    • Contact: Lise Laclautre; Phone Number: 334.73.754.963; Email: promo_interne_drci@chu-clermontferrand.fr
  • Clermont-Ferrand, France, 63000
    • Recruiting
    • CHU de Clermont-Ferrand
    • Principal Investigator: Marion COUDERC, MD
    • Contact: Lise Laclautre; Phone Number: 334.73.754.963; Email: promo_interne_drci@chu-clermontferrand.fr
  • Grenoble, France, 38000
    • Not yet recruiting
    • CHU de Grenoble
    • Principal Investigator: Philippe GAUDIN, MD, PhD
    • Contact: Lise Laclautre; Phone Number: 334.73.754.963; Email: promo_interne_drci@chu-clermontferrand.fr
  • Lyon, France, 69000
    • Not yet recruiting
    • Hospices Civils de Lyon
    • Contact: Lise Laclautre; Phone Number: 334.73.754.963; Email: promo_interne_drci@chu-clermontferrand.fr
    • Principal Investigator: Roland CHAPURLAT, MD, PhD
  • Montpellier, France, 34000
    • Not yet recruiting
    • CHU de Montpellier
    • Contact: Lise Laclautre; Phone Number: 334.73.754.963; Email: promo_interne_drci@chu-clermontferrand.fr
    • Principal Investigator: Jacques MOREL, MD, PhD
  • Paris, France, 75000
    • Not yet recruiting
    • Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Cochin
    • Principal Investigator: Maxime DOUGADOS, MD, PhD
    • Contact: Lise Laclautre; Phone Number: 334.73.754.963; Email: promo_interne_drci@chu-clermontferrand.fr
  • Saint-Étienne, France, 42000
    • Not yet recruiting
    • CHU de Saint-Etienne
    • Principal Investigator: Thierry THOMAS, MD, PhD
    • Contact: Lise Laclautre; Phone Number: 334.73.754.963; Email: promo_interne_drci@chu-clermontferrand.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• diagnosis of axial SpA defined by ASAS criteria
• Rheumatologist not wish to change the treatment within 4 months of inclusion,
• stable treatment (NSAID and/or DMARD) for at least 3 months but no corticosteroid infiltration in the month prior to inclusion,
• able to follow a GFD and to provide written informed consent and submit to the requirements of the study

Exclusion Criteria:

• Any diet at the time of inclusion or within 3 months prior to inclusion;
• have a history of celiac disease;
• received antibiotic treatment within 3 months of inclusion or are taking a probiotic;
• are pregnant, breastfeeding,
• not covered by social security;
• minors or adults under the protection of the law or under the protection of justice.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: experimental arm; In the experimental arm will receive at least 6 gluten-free breads per day + 200 g of gluten-free penne pasta per week + 6 rice flavor capsules per day	Dietary supplement: Gluten-Free Diet; Dietary supplement without gluten
Active Comparator: control arm; the control arm will received 6 gluten-containing breads per day + 200 g of gluten-containing penne pasta per week + 6 vital gluten-containing capsules per day	Dietary supplement: Gluten Diet; Dietary supplement with gluten

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of the variation in quality of life evaluated variation inby the Assessment of SpondyloArthritis international Society (ASAS) Health Index	The self-report questionnaire measures functioning and health across 17 aspects of health and 9 environmental factors (EF) in patients with SpA. The total sum of the ASAS HI ranges from 0-17, with a lower score indicating a better health status.	Change from baseline ASAS HI score at 16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
effects of a 16-week GFD versus placebo diet on the activity of SpA evaluated by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).	The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score. Scores of 4 or greater suggest suboptimal control of disease,	Change from baseline BASDAI score at 16 weeks
effects of a 16-week GFD versus placebo diet on parameters of inflammation evaluated by the erythrocyte sedimentation rate (ESR).	An ESR is a type of blood test that measures how quickly erythrocytes settle at the bottom of a test tube that contains a blood sample. Normally, red blood cells settle relatively slowly. A faster-than-normal rate may indicate inflammation in the body.	Change from baseline ESR at 16 weeks
effects of a 16-week GFD versus placebo diet on parameters of inflammation evaluated by the C-reactive protein (CRP)	A c-reactive protein test measures the level of c-reactive protein (CRP) in your blood. CRP is a protein made by your liver. It's sent into your bloodstream in response to inflammation. Normally, you have low levels of c-reactive protein in your blood. High levels may be sign of a serious infection or other disorder.	Change from baseline CRP at 16 weeks
effects of a 16-week GFD versus placebo diet on fatigue assessed by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale.	The FACIT Fatigue Scale is a short, 13-item, that measures an individual's level of fatigue during their usual daily activities over the past week. Score range 0-52. A score of less than 30 indicates severe fatigue. The higher the score, the better the quality of life	Change from baseline FACIT score at 16 weeks
effects of a 16-week GFD versus placebo diet on depression evaluated by the Hospital anxiety and depression scale (HAD)	The HAD scale is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. cut-off point of 8/21 for anxiety or depression	Change from baseline HAD score at 16 weeks
Variations in the abundance and type of different bacterial species found in the intestinal microbiota for a subgroup of patients	The microbiota will be analyzed in a subgroup of patients (n = 40) using stool samples collected at J0 and S16	Change from baseline abundance and types of bacteria at 16 weeks
effects of a 16-week GFD versus placebo diet on functional disability asssessed by Bath Ankylosing Spondylitis Functionnal Index (BASFI) questionnaire	Functional disability index consisting of 10 questions. The final score is calculated on 100 points. The higher the score, the greater the handicap.	Change from baseline BASFI score at 16 weeks and at 24 weeks
effects of a 16-week GFD versus placebo diet on the persistence of fibromyalgia syndrome	the Fibromyalgia rapid screening tool (FIRST) questionnaire makes it possible to screen for fibromyalgia syndrome quickly and easily. The FIRST questionnaire consists of 6 questions. A score of 5/6 or higher indicates definite fibromyalgia syndrome	Persistence of fibromyalgia syndrome at week 16 and 24 (if present at inclusion)
Evaluation of compliance with the GFD by an interview with the dietician	The patient's compliance to the GFD will be evaluated by the dietician using an online 3-day alimentary questionnaire. The patient will have to postpone all food consumed and its quantity during the last 3 days before the consultation with the dietician	at week 16
effects of a 16-week GFD versus placebo diet on body mass index (BMI)	The BMI will be calculated by the formula (height/weight²).	Change from baseline BMI at week 16 and 24
effects of a 16-week GFD versus placebo diet on Homeostasis Model Assessment of insulin resistance (HOMA-IR)	Insulin resistance will be calculated by the following formula : fasting blood glucose (mmol / l) x fasting insulin (μmol/l) /22.5. A score greater than or equal to 3 indicates insulin resistance	Change from baseline insulin resistance at week 16

Collaborators and Investigators

• Sponsor: University Hospital, Clermont-Ferrand
• Collaborators: Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement; PANZANI
• Investigators: Principal Investigator: Marion Couderc, MD, CHU de Clermont-Ferrand

Publications and helpful links

General Publications

• Couderc M, Pereira B, Schaeverbeke T, Thomas T, Chapurlat R, Gaudin P, Morel J, Dougados M, Soubrier M. GlutenSpA trial: protocol for a randomised double-blind placebo-controlled trial of the impact of a gluten-free diet on quality of life in patients with axial spondyloarthritis. BMJ Open. 2020 Nov 20;10(11):e038715. doi: 10.1136/bmjopen-2020-038715.

Study record dates

Study Major Dates

• Study Start (Actual): October 7, 2021
• Primary Completion (Estimated): October 1, 2023
• Study Completion (Estimated): March 1, 2024

Study Registration Dates

• First Submitted: February 11, 2020
• First Submitted That Met QC Criteria: February 14, 2020
• First Posted (Actual): February 18, 2020

Study Record Updates

• Last Update Posted (Actual): July 3, 2023
• Last Update Submitted That Met QC Criteria: June 29, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: gut microbiota; gluten-free diet; ankylosing spondylitis; spondyloarthritis
• Additional Relevant MeSH Terms: Infections; Joint Diseases; Musculoskeletal Diseases; Arthritis; Spinal Diseases; Bone Diseases; Spondylarthropathies; Bone Diseases, Infectious; Ankylosis; Spondylitis; Spondylarthritis; Spondylitis, Ankylosing; Axial Spondyloarthritis
• Other Study ID Numbers: PHRC IR 2017 COUDERC; 2018-A00309-46 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No